Company / Capital Expenditures
Foghorn Therapeutics Inc. Capital Expenditures History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
$906.0K
FY2025
5-year range
$906.0K / $16.2M
FY2021-FY2025
Trend
-26.0%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Capital Expenditures has fluctuated over the past 6 years, ranging from $906,000 in FY2025 to $16M in FY2021.
Based on SEC 10-K filings.
$906,000 in FY2025 with a 5-year CAGR of -1.3%.
Declined from $1M to $906,000 over the past 2 years.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- -35.1%
- 5-Year CAGR
- -1.3%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of -1.3%, indicating a declining trend.
- In FY2025, capital expenditures decreased 26.0% year-over-year.
- Peak capital expenditures was recorded in FY2021.
Company context
Key Data Points
- Low Piotroski F-Score: 0/9 (multiple financial health concerns)
- Altman Z-Score -1.20 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $906.0K | -26.0% |
| FY2024 | $1.2M | +1.2% |
| FY2023 | $1.2M | -63.5% |
| FY2022 | $3.3M | -79.5% |
| FY2021 | $16.2M | +1571.8% |
| FY2020 | $968.0K | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026